Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Salarius Pharmaceuticals Inc (SLRX) USD0.0001

Sell:$1.30 Buy:$1.49 Change: $0.26 (13.90%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.26 (13.90%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Change: $0.26 (13.90%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.

Contact details

2450 Holcombe Blvd Ste J-608
United States
+1 (617) 8741821

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$38.33 million
Shares in issue:
19.82 million
United States
US dollar

Key personnel

  • William McVicar
    Chairman of the Board
  • David Arthur
    President, Chief Executive Officer, Director
  • Mark Rosenblum
    Chief Financial Officer, Executive Vice President - Finance
  • Nadeem Mirza
    Senior Vice President - Clinical Development
  • Bruce Mccreedy
    Interim Chief Scientific Officer and Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.